Author | IUPAC name of the reported synthesized quinazoline/pyrrole derivatives | Cell line utilized | IC50 values (μM) | Standard IC50 values (μM) |
---|---|---|---|---|
Abuelizz et al. [24] | 2-(Allylthio)-3-butyl-6-methylquinazolin-4(3H)-one | Cervical cancer (HeLa) | 5.65 | Gefitinib (4.3) |
Human breast cancer (MDA-MB231) | 3.77 | Gefitinib (28.33) | ||
Abuelizz et al. [24] | Butyl-6-methyl-2-(2-methylbenzylthio)-quinazolin-4(3H)-one | Cervical cancer (HeLa) | 6.3 | Gefitinib (4.3) |
Human breast cancer (MDA-MB231) | 4.44 | Gefitinib (28.33) | ||
Madhavi et al. [25] | (E)-1-(4-(Trifluoromethyl)phenyl)-3-(4-(quinazolin-4-ylamino)phenyl)prop-2-en-1-one | Human alveolar adenocarcinoma cell line (A459) | 0.10 | Combretastatin-A4 (0.11) |
Human breast adenocarcinoma cell line (MCF-7) | 0.17 | Combretastatin-A4 (0.18) | ||
Madhavi et al. [25] | (E)-1-(4-Methoxyphenyl)-3-(4-(quinazolin-4-ylamino)phenyl)prop-2-en-1-one | Human alveolar adenocarcinoma cell line (A459) | 2.10 | Combretastatin-A4 (0.11) |
Human breast adenocarcinoma cell line (MCF-7) | 0.16 | Combretastatin-A4 (0.18) | ||
Regin et al. [26] | 1-(3-Aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)-methanone | Human cervical carcinoma (HeLa) | 30 | Vinblastin (10) |
A-549 (human lung carcinoma) | 10 | Vinblastin (20.2) | ||
Regin et al. [26] | 1-(4-Methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)-methanone | Human cervical carcinoma (HeLa) | 150 | Vinblastin (10) |
A-549 (human lung carcinoma) | 80 | Vinblastin (20.2) |